Skip to content

The effective of oxycodone intravenous patient-controlled analgesia on rebound pain following femoral nerve block after knee arthroplasty surgery

The effective of oxycodone intravenous patient-controlled analgesia on rebound pain following femoral nerve block after knee arthroplasty surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062497
Enrollment
Unknown
Registered
2022-08-09
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute postoperative pain

Interventions

Group C:Oxycodone 0.25mg/ml + normal saline to 200ml
background dose 0ml/h, bolus 4ml, interval 5min
Group P:Oxycodone 0.25mg/ml + saline to 200ml, background dose 1ml/h, Bolus 4ml, 5min interval
Group A:Oxycodone 0.25mg/ml + normal saline to 200ml, the first stage (0-6h after surgery): background dose 0ml/h, Bolus 4ml, interval 5min
the second stage (6-24h after surgery): background dose 1ml/h , Bolus 4ml, interval 5min
the third stage (24-72h after surgery): background dose 0ml/h, Bolus 4ml, interval 5min

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. 18 years old <= age <= 75 years old; 2. ASA I or II; 3. 18 kg/m2<BMI<30 kg/m2; 4. elective knee replacement surgery; 5. Received femoral nerve block therapy and postoperative patient-controlled intravenous analgesia (PCIA).

Exclusion criteria

Exclusion criteria: 1. Coagulation dysfunction; 2. Neuropsychiatric diseases requiring drug treatment; 3. Hypersensitivity to local anesthetics, flurbiprofen axetil, and contraindications for use; 4. Severe cardiopulmonary disease; 5. History of preoperative opioid use; 6. Poorly controlled diabetes; 7. Pregnancy or lactation; 8. History of previous knee surgery; 9. Communication barriers, inability to understand pain scores or patient-controlled intravenous analgesia; 10. Failure of nerve block or complications of nerve block are judged by the investigator to be incapable of enrolling in the group; 11. Abnormal liver and kidney function (aspartate aminotransferase (AST) or/and alanine aminotransferase (ALT) and/or total bilirubin (TBiL) >= 2*ULN; serum creatinine (Cr) >= 2*ULN, or dialysis subjects ;); 12. History of drug abuse and/or alcohol abuse in the past 3 months, and alcohol abuse means drinking more than 2 units of alcohol per day on average (1 unit = 360 ml of beer with 5% alcohol content or 45 ml of liquor with 40% alcohol content or 150ml wine; 13. Those who entered the ICU after surgery.

Design outcomes

Primary

MeasureTime frame
Differences in pain scores before and after nerve block disappearance;

Secondary

MeasureTime frame
Incidence of fulminant pain within 24 hours after operation;Onset and duration of rebound pain;Oxycodone consumption;Numerical rating scale, NRS;Zhènjìng píngfen 4 / 5,000 Translation results Sedation score;St. Mary's Hospital Sleep Score;EuroQol-5D (EQ-5D);Neuropathic pain;Satisfaction of patients and their families with postoperative analgesia treatment;

Countries

China

Contacts

Public ContactYingying Zhao

The First Affiliated Hospital of Zhengzhou University

zyy260340@163.com+86 13733198879

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026